Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383513 · ClinicalTrials.gov registry record · Phase 2
Study of Epratuzumab in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00383513 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 29 participants.
The verdict
NCT00383513, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
Epratuzumab is an investigational antibody designed to help treat Systemic Lupus Erythematosus (SLE). The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued maintenance-cycle administrations of Epratuzumab.
Interventions
- BIOLOGICAL Epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00383513
The ClinicalTrials.gov registry entry for NCT00383513 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epratuzumab is the first listed.
NCT00383513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00383513 about?
NCT00383513 is a clinical study titled "Study of Epratuzumab in Systemic Lupus Erythematosus". Epratuzumab is an investigational antibody designed to help treat Systemic Lupus Erythematosus (SLE). The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued maintenance-cycle administrations of Epratuzumab.
What is the current status of trial NCT00383513?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2006-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00383513?
The interventions under investigation include: Epratuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00383513?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.